Cost-utility analysis of methadone maintenance treatment: A methodological approach

被引:12
|
作者
Vanagas, G
Padaiga, Z
Bagdonas, E
机构
[1] Kaunas Univ Med, Dept Prevent Med, LT-50009 Kaunas, Lithuania
[2] Kaunas Univ Technol, Kaunas, Lithuania
关键词
maintenance treatment; economic evaluation; quality of life; cost accounting; cost-utility analysis;
D O I
10.1080/10826080500368751
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Economic considerations influence the substance user treatment system. These considerations influence who gets treatment and for how long, as well as determining what services they receive and in what setting. Current medical literature argues that maintenance treatment reduces risk-taking behavior, such as injection drug use and needle sharing. Treatment also reduces the mortality associated with abuse of opiates by injection and can cause decreases in costs incurred by the criminal justice system and social services agencies. This suggests the need for complex economic evaluations of a maintenance treatment to find out the optimum treatment program. This paper describes methods of economic evaluation in healthcare and reviews the methodology of cost-utility analysis in economic evaluations of methadone maintenance treatment.
引用
收藏
页码:87 / 101
页数:15
相关论文
共 50 条
  • [41] COST-UTILITY ANALYSIS OF NIVOLUMAB MONOTHERAPY FOR METASTATIC MELANOMA TREATMENT
    Echave, M.
    Oyaguez, I
    Soria, A.
    de la Cruz-Merino, L.
    Arance, A.
    Carrasco, M.
    Gonzalez Garcia, P.
    VALUE IN HEALTH, 2016, 19 (07) : A739 - A739
  • [42] Cost-utility analysis of tegaserod for the treatment of irritable bowel syndrome
    Chen, SY
    Lin, PJ
    Biddle, AK
    VALUE IN HEALTH, 2006, 9 (03) : A46 - A47
  • [43] AGOMELATIN FOR TREATMENT OF DEPRESSIVE DISORDERS IN RUSSIA: A COST-UTILITY ANALYSIS
    Ignatyeva, V. I.
    Frolov, M. Y.
    Avksentyeva, M. V.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E102 - E102
  • [44] Treatment costs in Hodgkin's disease: A cost-utility analysis
    Norum, J
    Angelsen, V
    Wist, E
    Olsen, JA
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) : 1510 - 1517
  • [45] A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE
    Teitsson, S.
    Bregman, B.
    Cotte, F. E.
    Augusto, M.
    Amadi, A.
    Moshyk, A.
    Roze, S.
    Gaudin, A. F.
    VALUE IN HEALTH, 2019, 22 : S448 - S448
  • [46] A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF PROSTATE CANCER IN CHINA
    Yang, F.
    Du, X.
    Xuan, J.
    Fei, J.
    VALUE IN HEALTH, 2019, 22 : S35 - S36
  • [47] Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
    Bregman, Bruno
    Teitsson, Siguroli
    Orsini, Isabella
    Cotte, Francois-Emery
    Amadi, Adenike
    Moshyk, Andriy
    Roze, Stephane
    Gaudin, Anne-Francoise
    DERMATOLOGY AND THERAPY, 2020, 10 (06) : 1331 - 1343
  • [48] Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis
    Leonart, Leticia P.
    Riveros, Bruno S.
    Krahn, Murray D.
    Pontarolo, Roberto
    NEUROENDOCRINOLOGY, 2021, 111 (04) : 388 - 401
  • [49] Treatment of primary pulmonary hypertension (PPH): A cost-utility analysis
    Tano, BD
    Sood, N
    Hoffmann, S
    Pathak, DS
    VALUE IN HEALTH, 2003, 6 (03) : 308 - 308
  • [50] BUPRENORPHINE/NALOXONE VERSUS BUPRENORPHINE AND METHADONE IN HEROIN ADDICTION DETOXIFICATION: AN ITALIAN COST-UTILITY ANALYSIS
    Marino, V
    Lazzaro, C.
    VALUE IN HEALTH, 2011, 14 (07) : A293 - A293